Ocrelizumab not checked
Roche · RO4964913 · PRO70769
FollowEvery change as it happens, and a Monday email
Trials
21 active
37 in total · 22 in the EU
What this is
- How it works
- An antibody that marks B cells (a type of immune cell) for destruction. Used in blood cancers and autoimmune disease.CD20-directed Cytolytic Antibody FDA class
- How it’s given
- “Ocrelizumab will be administered as per the schedule specified in the respective arms.”In the company’s words, NCT07483450 on ClinicalTrials.gov
- Tested for
- Multiple Sclerosis (8 trials), Multiple Sclerosis, Primary Progressive (2 trials), Relapsing-remitting Multiple Sclerosis (2 trials), Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, Progressive Multiple Sclerosis (PMS), Progressive Multiple Sclerosis
- Main trialPhase 4
- “The main purpose of this study is to evaluate the efficacy of ocrelizumab in participants with relapsing multiple sclerosis (RMS) and to characterize the ocrelizumab pharmacodynamic (PD) profile in Chinese participants with primary progressive multiple sclerosis (PPMS).”In the company’s words, NCT07483450 on ClinicalTrials.gov
- Other names
- Ocrevus · RO4964913 · OCR · PRO70769 · rhuMAb 2H7
- Given with
- Avonex (Biogen)Other companies’ drugs in its trials
Other drugs for Multiple Sclerosis
- IMU-838Immunic AG · Phase 3
- CT-P53Celltrion · Phase 3
- ABP 692Amgen · Phase 3
- FrexalimabSanofi · Phase 3
- Peginterferon beta-1aBiogen · Phase 3
- PrivosegtorOculis · Phase 3
Copies tested against it3
Other companies’ versions, mostly cheaper copies for when the patent ends
- CT-P53Celltrion · NCT05906992
- PB018Polpharma Biologics International AG · NCT07606521
- RPH-035R-Pharm · NCT07597668
Coming up6
- 31 Dec 2027Phase 4 trial completes · ClinicalTrials.gov
- 31 Dec 2027Phase 3 trial completes · ClinicalTrials.gov
- 30 May 2028Phase 2 trial completes · ClinicalTrials.gov
- 28 Feb 2029Phase 4 trial completes · ClinicalTrials.gov
- 31 Aug 2029Phase 2 trial completes · ClinicalTrials.gov
- 31 Dec 2029Phase 3 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 9 NovCompletion date moved: 2028-02-15 to 2026-09-01 · ClinicalTrials.gov NCT07667322
Trials37
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 4Active, not recruiting | 31 Dec 2027 | A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ocrelizumab in Participants With Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis | |
| Phase 4Recruiting | 28 Feb 2029 | A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy | |
| Phase 3Active, not recruiting | 19 Dec 2024 | A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS) | |
| Phase 3Active, not recruiting | 15 Jan 2025 | A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis | |
| Phase 3Active, not recruiting | 9 Jun 2025 | A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS) | |
| Phase 3Active, not recruiting | 30 Jun 2025 | A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS) | |
| Phase 3Active, not recruiting | 17 Sep 2025 | A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis | |
| Phase 3Active, not recruiting | 22 Oct 2026 | A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis | |
| Phase 3Active, not recruiting | 31 Dec 2027 | A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis | |
| Phase 3Recruiting | 31 Dec 2029 | An Extension Study to Assess Impact of Multiple Sclerosis (MS) on Physical Function and Provide Continued Ocrelizumab Treatment | |
| Phase 2Active, not recruiting | 5 Oct 2023 | A Study of Ocrelizumab in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis | |
| Phase 2Active, not recruiting | 17 Sep 2026 | A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS) | |
| Phase 2Recruiting | 30 May 2028 | A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS) | |
| Phase 2Not yet recruiting | 31 Aug 2029 | A Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogenicity and Pharmacodynamic Effects of Subcutaneous Ocrelizumab Administration in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS) | |
| Phase 1Active, not recruiting | 1 Sep 2026 | A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of a New Subcutaneous Formulation of Ocrelizumab in Participants With Multiple Sclerosis | |
| Phase 4Completed | 15 Feb 2021 | A Study to Provide Complementary Efficacy, Safety and Patient Reported Outcomes Data in Participants With Active Relapsing Forms of Multiple Sclerosis (MS) in a Pragmatic Setting | |
| Phase 4Completed | 15 Dec 2022 | Prospective Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) After Initiation and During Treatment With Ocrelizumab | |
| Phase 4Completed | 29 Mar 2024 | A Study Evaluating B Cell Levels In Infants Of Lactating Women With CIS Or MS Receiving Ocrelizumab | |
| Phase 4Completed | 8 Apr 2024 | A Study Evaluating B Cell Levels In Infants Potentially Exposed To Ocrelizumab During Pregnancy | |
| Phase 4Withdrawn | 31 Jan 2025 | A Study To Determine The Effect Of Ocrelizumab On Leptomeningeal Inflammation In Multiple Sclerosis | |
| Phase 3Completed | 2 Apr 2015 | A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis | |
| Phase 3Completed | 12 May 2015 | A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis | |
| Phase 3Completed | 23 Jul 2015 | A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis | |
| Phase 3Completed | 14 Feb 2017 | A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis | |
| Phase 3Completed | 25 Oct 2019 | A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT) | |
| Phase 3Completed | 10 Mar 2023 | A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis | |
| Phase 3Completed | 11 Apr 2023 | Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS) | |
| Phase 3Terminated | 27 Apr 2023 | Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS) | |
| Phase 3Completed | 17 Jul 2025 | This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS) | |
| Phase 2Completed | 9 Mar 2012 | A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis | |
| Phase 1Completed | 3 Jun 2025 | A Study To Investigate The Pharmacokinetics, Safety, And Tolerability Of Subcutaneous Ocrelizumab Administration In Participants With Multiple Sclerosis | |
| Phase 3Authorised | not given | For patients with active multiple sclerosis, impact of annual versus semi-annual infusions of ocrelizumab after 2 years of initial treatment on the absence of radiological disease activity at 2 years: a multicentre randomised controlled non-inferiority trial | |
| Phase 3Authorised | not given | Ocrelizumab VErsus Rituximab off-Label at the Onset of Relapsing MS Disease (OVERLORD-MS) | |
| Phase 3/4Authorised | not given | Efficacy, safety and cost-effectiveness of B cell tailored ocrelizumab versus standard ocrelizumab in relapsing remitting multiple sclerosis (BLOOMS): a randomized controlled trial | |
| Phase 4Authorised | not given | The use of therapeutic monitoring of ocrelizumab serum concentrations for personalized pharmacotherapy of relapsing-remitting and primary progressive multiple sclerosis | |
| Phase 3Authorised | not given | STOP-I-SEP_Disease modifying therapies withdrawal in inactive Secondary Progressive Multiple Sclerosis patients older than 50 years | |
| Phase 3Authorised | not given | A PHASE III, OPEN-LABEL, SINGLE-ARM, MULTI-CENTER STUDY TO EVALUATE THE SAFETY AND USE OF AN ON-BODY DELIVERY SYSTEM FOR THE SUBCUTANEOUS HOME ADMINISTRATION OF OCRELIZUMAB IN PATIENTS WITH MULTIPLE SCLEROSIS |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026